Change search
ReferencesLink to record
Permanent link

Direct link
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial
Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.;Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Nobels Vag 16, S-17165 Stockholm, Sweden.;Danderyd Hosp, Dept Infect Dis, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy. Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Nobels Vag 16, S-17165 Stockholm, Sweden.;Sormland Cty Council, Clin Res Ctr, Eskilstuna, Sweden..
Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau..
Indepth Network, Projecto Saude Bandim, Bissau, Guinea Bissau.;Kolding Cty Hosp, Dept Paediat, Kolding, Denmark..
2016 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 11, no 9, e0161495Article in journal (Refereed) Published
Abstract [en]

Background Artemether-lumefantrine (AL) was introduced for treatment of uncomplicated malaria in Guinea-Bissau in 2008. Malaria then resurged and recurrent malaria after treatment with AL and stock-outs of AL were common. This study therefore aimed to assess the efficacy of AL and identify an alternative second line antimalarial. Dihydroartemisinin-piperaquine (DP) was chosen as it has been shown to be safe and efficacious and to reduce the incidence of recurrent malaria. Methods and Findings In a multicentre randomised open-label non-inferiority clinical trial, AL or DP were given over 3 days to children aged 6 months-15 years with uncomplicated P. falciparummonoinfection. Intake was observed and AL was given with milk. Children were seen on days 0, 1, 2 and 3 and then weekly days 7-42. Recurring P. falciparumwere classified as recrudescence or new infections by genotyping. Between November 2012 and July 2015, 312 children were randomised to AL (n = 155) or DP (n = 157). The day 42 PCR adjusted per protocol adequate clinical and parasitological responses were 95% and 100% in the AL and DP groups respectively, Mantel-Haenszel weighted odds ratio (OR) 0.22 (95% CI 0-0.68), p = 0.022. In a modified intention to treat analysis in which treatment failures day 0 and reinfections were also considered as treatment failures adequate clinical and parasitological responses were 94% and 97% (OR 0.42 [95% CI, 0.13-1.38], p = 0.15). Parasite clearance and symptom resolution were similar with both treatments. Conclusions Both treatments achieved the WHO recommended efficacy for antimalarials about to be adopted as policy. DP was not inferior to AL for treatment of uncomplicated P. falciparum malaria in Guinea-Bissau.

Place, publisher, year, edition, pages
2016. Vol. 11, no 9, e0161495
National Category
Infectious Medicine Pediatrics
Identifiers
URN: urn:nbn:se:uu:diva-306266DOI: 10.1371/journal.pone.0161495ISI: 000383892100006PubMedID: 27649561OAI: oai:DiVA.org:uu-306266DiVA: diva2:1040197
Funder
Swedish Society of Medicine
Available from: 2016-10-26 Created: 2016-10-26 Last updated: 2016-10-26Bibliographically approved

Open Access in DiVA

fulltext(1858 kB)19 downloads
File information
File name FULLTEXT01.pdfFile size 1858 kBChecksum SHA-512
c39136888949cea7eeabfbadd42d91c269b02d72aa1a7eeee248e1dacfa4f37a01a5298d1cdb0c8158e60608f7eda0d44ee24585f11d44acf46ea773f5b5545c
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed
By organisation
Disciplinary Domain of Medicine and Pharmacy
In the same journal
PLoS ONE
Infectious MedicinePediatrics

Search outside of DiVA

GoogleGoogle Scholar
Total: 19 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 47 hits
ReferencesLink to record
Permanent link

Direct link